NP / PA
Clark, Mark
Clark, Mark was paid $47K by Medicaid between Jun 2020 and Mar 2023, across 6 billing codes. Its largest line is S9083, Global fee urgent care centers — 47% of everything it billed.
33Billing provider infoCLARK, MARK
GREENFIELD, NH 03047
GREENFIELD, NH 03047
33aNPI1235115213assigned 12/21/2005
33bProvider typePhysician Assistant
28Total paid$47K
24GClaims571
24DCodes billed6
24AFirst – last monthJun 2020 – Mar 2023
Compared with peers
Next to other Physician Assistant providers in New Hampshire
Rank by total paid#6 of 18
Median peer was paid$3K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 410 | $29K | |
| 2021 | 12 | $2K | |
| 2022 | 121 | $13K | |
| 2023 | 28 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| S9083 | Global fee urgent care centers | 47% | 179 | 178 | $22K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 27% | 123 | 102 | $13K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 219 | 190 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 17 | 16 | $687.14 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 14 | 14 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 19 | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.